Aug 10, 2026 – 1.02pmThree months ago, Jardine Matheson splashed $3.4 billion acquiring I-MED’s Australian and New Zealand operations and leaving no doubt in the minds of buyout firms that radiology assets were seriously in demand.Now, the spotlight is on Everlight Radiology, which was placed on the sale block last year by private equity owner Livingbridge and makes more $70 million in earnings before interest, tax, depreciation and amortisation.Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Angira Bharadwaj is a co-editor of Street Talk. She covers IPOs, capital raises, mergers and acquisitions and other breaking news in Australia’s capital markets. Previously, she covered financial services, state, and federal politics. Send tips to @angirab.60 on encrypted messaging platform Signal.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
Three’s a crowd at Livingbridge’s $1b-plus Everlight Radiology sale
Three motivated bidders are preparing to submit binding offers by Friday for the world’s largest teleradiology business.
TL;DRAI
Livingbridge sells Everlight Radiology ($70M+ EBITDA) following Jardine Matheson's $3.4B I-MED Australasia acquisition. Radiology assets see strong M&A demand with elevated multiples—signals medical imaging AI consolidation favoring profitable platforms.
181 words~1 min read
